0001127602-24-001603.txt : 20240118
0001127602-24-001603.hdr.sgml : 20240118
20240118165506
ACCESSION NUMBER: 0001127602-24-001603
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240117
FILED AS OF DATE: 20240118
DATE AS OF CHANGE: 20240118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eisele Jeffrey
CENTRAL INDEX KEY: 0001827326
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24542476
MAIL ADDRESS:
STREET 1: APELLIS PHARMACEUTICALS, INC.
STREET 2: 100 5TH AVENUE, 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-01-17
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001827326
Eisele Jeffrey
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Chief Development Officer
1
Common Stock
2024-01-17
4
S
0
5207
65.58
D
67443
D
This is a scheduled sale from an established 10b5-1 plan.
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
2024-01-18